Stroke research under funded in Europe, perhaps the world

August 12, 2004

DALLAS, August 13 - Despite being the second leading cause of death worldwide, funding for stroke research lags far behind funding for other major causes of death in Europe, according to a study in Stroke: Journal of the American Heart Association.

Previous studies in the United States had similar findings, indicating that under funding of stroke research may be a worldwide problem that has potentially devastating health and economic implications, said lead researcher Sarah T. Pendlebury, B.M., B.Ch., an internal medicine specialist at John Radcliffe Hospital in Oxford, United Kingdom.

Researchers who reviewed funding patterns in nine European countries concluded that compared to coronary heart disease (CHD) and cancer, stroke received substantially less funding for research. In most countries, cancer research received at least 10 times more funding than did stroke research.

"As a consequence of the aging population in both the developed and developing world, it is projected that stroke will shortly become the most common cause of premature death worldwide," said senior author Peter M. Rothwell, M.D., Ph.D., professor of clinical neurology at the University of Oxford. "Stroke is already the most common neurological disorder in Europe and the most common cause of neurological disability in the developed world. Research into acute treatment and rehabilitation are important, but research into stroke prevention is absolutely vital if we are to offset the projected increase in the clinical and financial burden of stroke."

To determine the scope of the under funding phenomenon, a group of investigators reviewed financial data from 2000 to 2001 from nine countries (Belarus, Estonia, Switzerland, Turkey, Norway, Netherlands, Austria, U.K., and Poland). The review focused on research funding distributed by healthcare associations, charities and government-funded organizations and included funding for CHD, cancer, and stroke research. The information was gleaned from annual reports, Internet web sites, and from direct communication with the associations and organizations.

Stroke funding as a percentage of the total funding for stroke, CHD and cancer was uniformly low, ranging from 2 percent to 11 percent across the different countries.

Researchers compared stroke funding to cancer-related funding. Stroke funding ranged from 2 percent of total cancer-related funding in Norway and the Netherlands to 17 percent of total cancer-related funding in Switzerland.

They also compared stroke research funding to CHD research funding. Funding for stroke research lagged far behind in eight of the nine countries, ranging between 2 percent (Austria) and 58 percent (Switzerland). Only Turkey allocated more funding for stroke research (38 percent more) than for CHD research.

"This low stroke research funding occurs despite healthcare costs that are at least as high and probably higher for stroke as cancer and CHD," researchers said.

Rothwell acknowledged that the lower funding of stroke research probably reflects public misperceptions about stroke.

"The public perception is that stroke is something that people die of or that it only occurs in the very elderly," he said. "Ironically, both are completely wrong. You are less likely to die of a stroke than a heart attack, but you are much more likely to be left with major disability. And 50 percent of strokes occur in people under 75 years of age.

"Strangely, the public tends to fear stroke much more than heart attack because of the thought of being left dependent; yet, people don't tend to give so generously to stroke charities. Perhaps stroke is a condition they just don't like to think about."

The most obvious way to correct the imbalance in funding would be for government agencies that fund healthcare research to make funding proportional to the clinical burden of the disease in society, Rothwell continued. Few agencies currently allocate research funding in that manner. With respect to allocation of available funds for stroke research, he encouraged putting far more money into stroke prevention.

"I think all areas are in need, but in terms of potential impact on the burden of the disease, prevention must be the major priority," Rothwell said. "More than perhaps any other condition, prevention is better than cure when it comes to stroke."

According to the American Stroke Association - a division of the American Heart Association - the estimated direct and indirect cost of stroke in the United States in 2004 will be $53.6 billion.

"In the United States, stroke is the No. 3 killer and a leading cause of disability," said Robert J. Adams, M.D., chairperson of the American Stroke Association advisory committee. "Ideally, funding for disease research should be proportional to its impact on society and on the opportunities available for progress in science."
-end-
Co-authors of the study are Ale Algra, M.D., Ph.D.; Marie-José Ariesen, M.Sc.; Goksel Bakac, M.D.; Anna Czlonkowska, M.D.; Alexandra Dachenhausen, Ph.D.; Yakup Krespi, M.D.; Janika Kõrv, M.D., Ph.D.; Konrad Krolikowski, M.D.; Sergey Kulesh, M.D.; Patrik Michel, M.D.; Lars Thomassen, M.D.; Maria Gugging; Julien Bogousslavsky M.D. and Michael Brainin, M.D., Ph.D.

Statements and conclusions of study authors that are published in the American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect association policy or position. The American Heart Association makes no representation or warranty as to their accuracy or reliability.

Editor's note: For more information on stroke, visit the American Stroke Association Web site: strokeassociation.org.

CONTACT: For journal copies only,
please call: (214) 706-1396
For other information, call:
Bridgette McNeill: (214) 706-1135
Carole Bullock: (214) 706-1279
Julie Del Barto (broadcast): (214) 706-1330

American Heart Association

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.